Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review

Mohamed Farag, Visvesh Jeyalan, Jose Luis Ferreiro, Young-Hoon Jeong, Tobias Geisler, Diana A. Gorog

Research output: Contribution to journalReview articlepeer-review

1 Downloads (Pure)

Abstract

Current guidelines for patients with acute coronary syndrome (ACS) recommend dual antiplatelet therapy (DAPT) for 12 months. Since bleeding is the main Achilles' heel of DAPT, in recent years several randomized controlled trials have evaluated the safety and efficacy of de-escalation of DAPT with respect to ischaemic and bleeding endpoints. These trials can be broadly divided into studies evaluating a shorter duration of DAPT, and those studies in which DAPT that includes a potent P2Y12 inhibitor, such as prasugrel or ticagrelor, is compared to less intense DAPT, mainly clopidogrel or reduced-dose prasugrel. We sought to evaluate the studies assessing de-escalation of DAPT in patients with ACS undergoing PCI. We review the studies evaluating the strategies of de-escalation of DAPT intensity and those evaluating a strategy of de-escalation of DAPT duration in ACS patients undergoing PCI. We summarize the limitations of studies to date, gaps in evidence and make recommendations for future studies.
Original languageEnglish
Article number1018649
Pages (from-to)1018649
Number of pages24
JournalFrontiers in Cardiovascular Medicine
Volume9
Early online date20 Oct 2022
DOIs
Publication statusPublished - 20 Oct 2022

Keywords

  • Cardiovascular Medicine
  • acute coronary syndrome
  • PCI
  • antiplatelet therapy
  • P2Y12 inhibitor
  • de-escalation
  • P2Y inhibitor

Fingerprint

Dive into the research topics of 'Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review'. Together they form a unique fingerprint.

Cite this